Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing. Adults with primary primary appendiceal ...

Jan. 28, 2025 — A data analysis from a randomized clinical trial for stage 3 colon cancer patients found that patients with evidence of residual cancer in their blood after surgery to remove the ...

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has significantly improved ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

Background: Variable rates of HER2 protein overexpression and gene ... they had measurable lesions (n = 4) or elevated cancer antigen 125 level and non-measurable lesions (n = 3).

Peakstock - stock.adobe.com A new DNA test developed in the UK can accurately predict whether high-risk patients will develop colorectal cancer in the five years. People with inflammatory bowel ...

Adenomatous polyps typically do not cause symptoms unless they progress to colon cancer. Even then, there may be no sign of a problem until the malignancy is advanced. This is why colon cancer ...